ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

2 years ago 207

Shares of ChemoCentryx Inc. CCXI, +5.43% soared 80.3% successful premarket trading connected Friday aft the institution said that it had received support from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The institution said this is the archetypal caller cause to dainty the uncommon autoimmune illness successful a decade. ChemoCentryx's banal slipped 68.3% this year, portion the broader S&P 500 SPX, +0.83% is up 16.1%.

Read Entire Article

ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

Related

How To Reach New Markets with Targeted Guest Blog Contributi...

Ten tips to lower your federal income tax bill before 2021 e...

Dollar Steady as Omicron Shadows Asia Market Open: Markets W...

6 Signs You Have a Toxic Workplace

Trending

Popular

Muḥammad ibn Mūsā al-Khwārizmī

Shed Long Jr. clubs go-ahead homer in eighth inning to give ...

Southern Baptist Convention Elects Ed Litton as New Presiden...

Jessica Biel didn't mean to have 'a secret Covid baby'

Multigenerational households a factor in covid-19 ethnic dis...